SMS Lifesciences Quarterly Results
SMS Lifesciences quarterly results. In Mar 2025, SMS Lifesciences (SMSLIFE) reported revenue ₹92 Cr and net profit ₹4 Cr. Review SMS Lifesciences price earnings to evaluate earnings-based valuation against sector peers.
SMSLIFE Quarterly Results — Revenue, Profit & EPS Highlights
SMS Lifesciences latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Check SMSLIFE company valuation to track the company's total market size over time.
- Revenue of ₹92 Cr in Mar 2025 (+9.5% vs Jun 2025, +0.0% vs Mar 2024)
- Net Profit of ₹4 Cr in Mar 2025 (+0.0% vs Jun 2025, -42.9% vs Mar 2024)
- EBITDA of ₹10 Cr in Mar 2025 (-23.1% vs Jun 2025)
- Operating Margin of 8.0% in Mar 2025 (-6.0pp vs Jun 2025)
- Earnings Per Share of ₹9.83 in Mar 2025 (-28.5% vs Jun 2025)
SMS Lifesciences Quarterly Results — Revenue, EBITDA, Net Profit & EPS
SMSLIFE quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2025 | Jun 2025 | Sept 2024 | Mar 2024 | Jun 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 92 | 84 | 81 | 92 | 93 | 9.5% | - |
| Net Profit (₹ Cr) | 4 | 4 | 3 | 7 | 7 | - | - |
| EBITDA (₹ Cr) | 10 | 13 | 11 | 14 | 17 | - | - |
| EPS (₹) | 9.83 | 13.75 | 15.46 | 19.53 | 23.15 | - | - |
| Operating Margin (%) | 8.0% | 14.0% | 11.0% | 13.0% | 18.0% | - | - |
SMSLIFE Share Price Trend — 1-Year Movement Across Quarterly Results
SMS Lifesciences 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit SMS Lifesciences screener.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
SMSLIFE vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
SMS Lifesciences latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹432,120.23 Cr | 1804.1 | 15,018 | 2,710 | -5.6% | - | 18.0% | 159.7 |
|
Divis Laboratories
Mar 2026 |
₹244,124.91 Cr | 9550.0 | 2,986 | 751 | -5.0% | - | 25.2% | 337.3 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4772.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 414.6 |
|
Zydus Life Science
Mar 2026 |
₹113,615.69 Cr | 1159.5 | 7,569 | 1,341 | -4.3% | - | 17.7% | 91.7 |
|
Laurus Labs
Mar 2026 |
₹109,629.35 Cr | 2050.0 | 1,823 | 282 | -10.5% | - | 15.5% | 396.5 |
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores